Articles & Affiliations

Dr Brahmer’s research paved the way for the first immunotherapy agent to receive US Food and Drug Administration approval for the treatment of lung cancer.

The Role of Immunotherapy in Early-Stage NSCLC

Combination Immunotherapy Approaches: A five-part video roundtable series

This is Part 1 of Appropriate Management of Challenging Cases in Lung Cancer, a five-part video roundtable series. Scroll down to watch the other videos from this Roundtable. View Video

This is Part 2 of Appropriate Management of Challenging Cases in Lung Cancer, a five-part video roundtable series. Scroll down to watch the other videos from this Roundtable. View Video

This is Part 3 of Appropriate Management of Challenging Cases in Lung Cancer, a five-part video roundtable series. Scroll down to watch the other videos from this Roundtable. View Video

This is Part 4 of Appropriate Management of Challenging Cases in Lung Cancer, a five-part video roundtable series. Scroll down to watch the other videos from this Roundtable. View Video

This is Part 5 of Appropriate Management of Challenging Cases in Lung Cancer, a five-part video roundtable series. Scroll down to watch the other videos from this Roundtable. View Video

Five-year results of immunotherapy for lung cancer: A discussion with Dr. Julie Brahmer

Lung Cancer Expert Julie R. Brahmer, MD, MSc, Was an Early Believer in Immunotherapy—and Still Is

Using Immune Checkpoint Inhibitors in Lung Cancer

Chemotherapy for Advanced Stage Non-Small Cell Lung Cancer

Breaking Research News from Annual Meeting of American Society of Clinical Oncology

Dr. Julie Brahmer, MD, Named March LUNGevity Hero for Research in Groundbreaking Field of Immunotherapy

AACR: Lung Cancer Therapy Innovations

Julie R. Brahmer, MD., MSc is recognized by Continental Who’s Who

Dr. Julie Brahmer is an associate professor of oncology at the Sidney Kimmel Comprehensive Cancer Center at John Hopkins Hospital